Since healthy volunteers usually have no expected direct clinical benefits in clinical trial, it is particularly important to fully assess the risks and carry out safety monitoring in all links of the trial in combination with their group characteristics. The risk points for healthy volunteers to participate in clinical trials lie in the aspects of trial drugs, clinical trial design, and trial implementation process. The safety and rights of healthy volunteers should be better protected by implementing the Good Pharmacovigilance Practices, improving the level of risk management, enhancing the transparency of clinical trial results, and carrying out relevant risk management research.

Since healthy volunteers usually have no expected direct clinical benefits in clinical trial, it is particularly important to fully assess the risks and carry out safety monitoring in all links of the trial in combination with their group characteristics. The risk points for healthy volunteers to participate in clinical trials lie in the aspects of trial drugs, clinical trial design, and trial implementation process. The safety and rights of healthy volunteers should be better protected by implementing the Good Pharmacovigilance Practices, improving the level of risk management, enhancing the transparency of clinical trial results, and carrying out relevant risk management research.